Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nanobiotix (NBTX) Current Deferred Revenue (2021 - 2025)

Nanobiotix has reported Current Deferred Revenue over the past 5 years, most recently at $42.1 million for Q4 2025.

  • For Q4 2025, Current Deferred Revenue rose 117.86% year-over-year to $42.1 million; the TTM value through Dec 2025 reached $42.1 million, up 117.86%, while the annual FY2025 figure was $42.1 million, 117.86% up from the prior year.
  • Current Deferred Revenue for Q4 2025 was $42.1 million at Nanobiotix, up from $40.9 million in the prior quarter.
  • Over five years, Current Deferred Revenue peaked at $42.1 million in Q4 2025 and troughed at $16.9 million in Q4 2022.
  • A 5-year average of $24.0 million and a median of $19.4 million in 2023 define the central range for Current Deferred Revenue.
  • Biggest five-year swings in Current Deferred Revenue: dropped 10.72% in 2022 and later skyrocketed 117.86% in 2025.
  • Year by year, Current Deferred Revenue stood at $18.9 million in 2021, then dropped by 10.72% to $16.9 million in 2022, then rose by 15.56% to $19.5 million in 2023, then decreased by 0.68% to $19.3 million in 2024, then skyrocketed by 117.86% to $42.1 million in 2025.
  • Business Quant data shows Current Deferred Revenue for NBTX at $42.1 million in Q4 2025, $40.9 million in Q2 2025, and $19.3 million in Q4 2024.